News|Articles|November 17, 2026

IDE849 Gains FDA Alignment on Registrational Trials in Neuroendocrine Carcinomas

Fact checked by: Roman Fabbricatore

After an FDA Type C meeting, registrational trials of the DLL3-targeting ADC IDE849 in pretreated neuroendocrine carcinomas are set to begin by year-end.

IDEAYA Biosciences has aligned with the FDA on registrational trial designs for IDE849 in patients with previously treated neuroendocrine carcinomas (NEC) following a Type C meeting, supporting a path toward potential accelerated and full approval of the investigational delta-like ligand 3 (DLL3)–targeting antibody-drug conjugate (ADC), according to a news release from the company.1

The developer plans to initiate a single-arm extension cohort in gastroenteropancreatic NEC (GEP-NEC) within the ongoing phase 1/2 IDE849-001 trial (NCT07174583) and a randomized phase 3 trial across multiple NEC subtypes, along with a separate phase 3 trial in extensive-stage small cell lung cancer (ES-SCLC), by the end of 2026.

What registrational trials are planned for IDE849 in NEC?

The single-arm extension cohort will enroll approximately 90 patients with previously treated GEP-NEC to support a potential accelerated approval. Patients will receive IDE849 at 2.4 mg/kg or 3.5 mg/kg intravenously once every 3 weeks. The primary end point is confirmed overall response rate (ORR) by blinded independent central review (BICR), supported by duration of response.

The developer also plans to submit a protocol for a randomized phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and large cell neuroendocrine carcinoma (LC-NEC). Progression-free survival (PFS) will serve as the primary end point for potential accelerated approval and overall survival (OS) as the primary end point for potential full approval. The company expects this trial to be well underway or fully enrolled when topline results from the single-arm cohort become available, positioning it to confirm clinical benefit and potentially expand the indication to additional NEC subtypes.

In ES-SCLC, IDEAYA is on track to start a randomized phase 3 trial of IDE849 monotherapy in patients previously treated with tarlatamab-dlle (Imdelltra) by year-end 2026, and the company is evaluating first-line combination designs.

What efficacy has IDE849 shown in neuroendocrine carcinomas?

Updated phase 1 data, presented by IDEAYA's partner, Jiangsu Hengrui Pharmaceuticals (Hengrui), at the 2026 European Society for Medical Oncology (ESMO) Congress, showed that among 19 patients with NEC who received IDE849 at doses of 1.8 mg/kg or higher every 3 weeks, the ORR was 52.6% (n = 10/19; 95% CI, 28.9%-75.6%) and the confirmed ORR was 36.8% (n = 7/19; 95% CI, 16.3%-61.6%). The disease control rate was 84.2% (n = 16/19), the median PFS was 7.0 months, and the estimated 9-month OS rate was 82.4%.

Across 122 patients treated in the trial, grade 1 or 2 interstitial lung disease (ILD) occurred in 6.6% of patients and grade 3 or higher ILD in 0.8%. In the global phase 1/2 expansion, grade 3 or higher treatment-related adverse events occurred in 5% (n = 1/20) of patients treated at 2.4 mg/kg and 22.2% (n = 4/18) of those treated at 3.5 mg/kg.

“NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy,” stated Yujiro S. Hata, president and chief executive officer of IDEAYA Biosciences, in the news release.1

What is IDE849 and how does it work?

IDE849, also known as SHR-4849, is an investigational ADC that pairs a humanized anti-DLL3 IgG1 antibody with a topoisomerase I (TOP1) inhibitor payload through a cleavable linker. DLL3 is expressed in ES-SCLC and other NECs, including bladder and cervical NECs. The company licensed development and commercialization rights to IDE849 outside Greater China from Hengrui in December 2024.

The ongoing global phase 1/2 IDE849-001 trial is evaluating IDE849 alone and in combination with durvalumab (Imfinzi) or IDEAYA's investigational PARG inhibitor IDE161 in patients with DLL3-expressing tumors, including SCLC and high-grade NEC.2

The company noted that the FDA's feedback is preliminary and nonbinding, and that the agency could require design changes or additional data before approval. IDE849 is not approved by the FDA or any other regulatory authority.

References

  1. IDEAYA Biosciences announces successful US FDA Type C meeting on phase 2/3 registrational trial designs to support potential accelerated and full approval for IDE849, a potential best-in-class DLL3 TOP1 ADC, in neuroendocrine carcinomas. News release. IDEAYA Biosciences, Inc. November 16, 2026. Accessed November 17, 2026. https://tinyurl.com/2xh2nhf7
  2. A study of IDE849 in patients with DLL3 expressing tumors including small cell lung cancer. ClinicalTrials.gov. Updated July 9, 2026. Accessed November 17, 2026. https://tinyurl.com/5f8ymfjm

Related to this article